Table 3.
Clinical Trial ID | Disease Condition | Study Phase | Combination Drugs | Status at Time of Search |
---|---|---|---|---|
NCT00444015 | Stage IIIB/IV disease Recurrent NSCLC | Phase I | Erlotinib + Dasatinib | Completed |
NCT02954523 | EGFR mut NSCLC | Phase I/II | Dasatinib + osimertinib | Active, not recruiting |
NCT00996723 | Diffuse Intrinsic Pontine Glioma | Phase I | Vandetanib + dasatinib | Completed |